These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 26316906)

  • 1. Economic evaluation of sacral neuromodulation in overactive bladder: A Canadian perspective.
    Hassouna MM; Sadri H
    Can Urol Assoc J; 2015; 9(7-8):242-7. PubMed ID: 26316906
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness of sacral neuromodulation compared to botulinum neurotoxin a or continued medical management in refractory overactive bladder.
    Arlandis S; Castro D; Errando C; Fernández E; Jiménez M; González P; Crespo C; Staeuble F; Rodríguez JM; Brosa M
    Value Health; 2011; 14(2):219-28. PubMed ID: 21402292
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-Effectiveness Analysis Between Sacral Neuromodulation and OnabotulinumtoxinA for the Treatment of Refractory Overactive Bladder in Women: A Systematic Review.
    Gerjevic KA; Ahmad S; Strohbehn K; Riblet N
    Female Pelvic Med Reconstr Surg; 2021 Aug; 27(8):481-487. PubMed ID: 34074937
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sacral neuromodulation in patients with refractory overactive bladder symptoms after failed Botulinum toxin therapy: Results in a large cohort of patients.
    Reekmans M; Janssen JMW; Vrijens DMJ; Smits MAC; van Koeveringe GA; Van Kerrebroeck PEVA
    Neurourol Urodyn; 2021 Jun; 40(5):1120-1125. PubMed ID: 33829519
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sacral neuromodulation and Botulinum toxin A for refractory idiopathic overactive bladder: a cost-utility analysis in the perspective of Italian Healthcare System.
    Bertapelle MP; Vottero M; Popolo GD; Mencarini M; Ostardo E; Spinelli M; Giannantoni A; D'Ausilio A
    World J Urol; 2015 Aug; 33(8):1109-17. PubMed ID: 25218855
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mechanism and Priority of Botulinum Neurotoxin A versus Sacral Neuromodulation for Refractory Overactive Bladder: A Review.
    Zhang Y; Ji F; Liu E; Wen JG
    Urol Int; 2021; 105(11-12):929-934. PubMed ID: 34130295
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The cost-effectiveness of sacral nerve stimulation (SNS) for the treatment of idiopathic medically refractory overactive bladder (wet) in the UK.
    Autiero SW; Hallas N; Betts CD; Ockrim JL
    BJU Int; 2015 Dec; 116(6):945-54. PubMed ID: 25407358
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness analysis of sacral neuromodulation and botulinum toxin A treatment for patients with idiopathic overactive bladder.
    Leong RK; de Wachter SG; Joore MA; van Kerrebroeck PE
    BJU Int; 2011 Aug; 108(4):558-64. PubMed ID: 21166750
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sacral neuromodulation for the treatment of overactive bladder: systematic review and future prospects.
    Tilborghs S; De Wachter S
    Expert Rev Med Devices; 2022 Feb; 19(2):161-187. PubMed ID: 35061951
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sacral neuromodulation for female pelvic floor disorders.
    El-Azab AS; Siegel SW
    Arab J Urol; 2019 Mar; 17(1):14-22. PubMed ID: 31258941
    [No Abstract]   [Full Text] [Related]  

  • 11. Sacral neuromodulation system for treating refractory overactive bladder.
    Phillips A
    Br J Nurs; 2020 Oct; 29(18):S30-S37. PubMed ID: 33035097
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Botox rechallenge-An additional tool in the management of an incompletely emptying bladder and inadequate overactive symptom control following sacral neuromodulation.
    Timm B; Jayarajan J; Chan G; Bolton D
    Low Urin Tract Symptoms; 2021 Jan; 13(1):194-197. PubMed ID: 32548938
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost profiles and budget impact of rechargeable versus non-rechargeable sacral neuromodulation devices in the treatment of overactive bladder syndrome.
    Noblett KL; Dmochowski RR; Vasavada SP; Garner AM; Liu S; Pietzsch JB
    Neurourol Urodyn; 2017 Mar; 36(3):727-733. PubMed ID: 27062384
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Variable frequency stimulation of sacral neuromodulation in black-zone overactive bladder patients: a case report.
    Meng L; Diao T; Wang M; Liu X; Zhang W; Tian Z; Wang J; Zhang Y
    Transl Androl Urol; 2020 Dec; 9(6):2842-2847. PubMed ID: 33457256
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Using electroacupuncture with optimized acupoint positioning to predict the efficacy of sacral neuromodulation of refractory overactive bladder: A case report.
    Shen J; Luo R; Zhang L; Li Y; Ke L; Gao Z
    Medicine (Baltimore); 2019 Nov; 98(45):e17795. PubMed ID: 31702631
    [TBL] [Abstract][Full Text] [Related]  

  • 16. What uro-gynecologists should know about sacral neuromodulation (SNM) for the treatment of refractory overactive bladder.
    Oelke M; Addali M; Reisenauer C
    Arch Gynecol Obstet; 2019 May; 299(5):1243-1252. PubMed ID: 30941558
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-Effectiveness of Sacral Neuromodulation versus OnabotulinumtoxinA for Refractory Urgency Urinary Incontinence: Results of the ROSETTA Randomized Trial.
    Harvie HS; Amundsen CL; Neuwahl SJ; Honeycutt AA; Lukacz ES; Sung VW; Rogers RG; Ellington D; Ferrando CA; Chermansky CJ; Mazloomdoost D; Thomas S
    J Urol; 2020 May; 203(5):969-977. PubMed ID: 31738113
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Results of a prospective, randomized, multicenter study evaluating sacral neuromodulation with InterStim therapy compared to standard medical therapy at 6-months in subjects with mild symptoms of overactive bladder.
    Siegel S; Noblett K; Mangel J; Griebling TL; Sutherland SE; Bird ET; Comiter C; Culkin D; Bennett J; Zylstra S; Berg KC; Kan F; Irwin CP
    Neurourol Urodyn; 2015 Mar; 34(3):224-30. PubMed ID: 24415559
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sacral neuromodulation for refractory overactive bladder after prior intravesical onabotulinumtoxinA treatment.
    Hoag N; Plagakis S; Pillay S; Edwards AW; Gani J
    Neurourol Urodyn; 2017 Jun; 36(5):1377-1381. PubMed ID: 27612039
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and tolerance of botulinum toxin injections after sacral nerve stimulation failure for idiopathic overactive bladder.
    Baron M; Perrouin-Verbe MA; Lacombe S; Paret F; Le Normand L; Cornu JN
    Neurourol Urodyn; 2020 Mar; 39(3):1012-1019. PubMed ID: 32108383
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.